A phase III placebo-controlled study in advanced head and neck cancer using intratumoural cisplatin/epinephrine gel.

Br J Cancer · 2002 · PMC2364322 · PMID 12434280

Europe PMC DOI

hedged sentence

0.0550

closest p · 1.1× alpha

0.0550

boldest claim

The sentences

borderline significanceP =0.055so close (0.05 < p ≤ 0.1)

Responding target tumours, as opposed to non-responding target tumours, tended to develop more erosion (47 vs 32%), necrosis (87 vs 47%), and eschar (33 vs 18%), although these differences were not statistically significant (borderline significance, CMH exact test P =0.055, was found for eschar).

also in 4,352 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.